Adenovirus (Ad5) mediated gene therapy for prostate cancer offers a new therapeutic modality. Payloads of various origins (cytotoxic, immunomodulatory, repair genes) have been applied in experimental settings and even in clinical phase I trials to alter tumour growth. We report here on in vitro studies of adenoviral constructs with altered tropism and a new therapeutic gene.
Vector Targeting. Currently, intraprostatic injection is used to target vectors to the prostate. Transcriptional targeting of genes under control of prostate speci®c promoters has been shown to be speci®c but is limited by a lower expression compared to viral promoters. Increasing the transduction of the vector into the cell might enhance the expression of therapeutic genes. The adenovirus uses the Coxsackie Adenoviral Receptor (CAR) for adhesion to the cell membrane by means of its viral knob, after which internalisation follows. Many tumour cells, including poorly differentiated prostate cancer cells, have limited or absent CAR. We have evaluated possibilities to retarget adenoviral vectors towards the pantumoral EpCAM antigen and prostate speci®c membrane antigen (PSMA) in order to increase transduction in vitro.
Method
Bi-speci®c antibodies constructed as conjugates between monoclonal anti-knob and monoclonal alpha-323 (Mab against EpCAM) or J591 (Mab against PSMA) were incubated with Ad5-CMV-EGFP to retarget the vector. Expression of EGFP was determined by FACS analysis in various prostate cancer cell lines (DU-145, PC-3, LNCaP and PC-346C) and non-prostatic controls.
Results
Receptor speci®c transduction of the vectors to EpCAM and PSMA was obtained, and retargeting was selective for prostate cancer cell lines in the case of PSMA. An increased expression of the transgene was seen after retargeting to poorly differentiated cell lines DU-145, and PC-3.
Therapeutic gene: MMAC/PTEN. The protein/lipid phosphatase MMAC/PTEN is a highly mutated tumour-suppressor gene. MMAC/PTEN exerts multiple functions, such as induction of cell cycle arrest and apoptosis. Furthermore, MMAC/PTEN is involved in cell adhesion, migration and differentiation. In clinical prostate cancer and xenografts, inactivation of the MMAC/PTEN gene is reported in up to 50% of clinical samples.
The androgen sensitive PC-346C cell line has been established from the PC-346 human prostate cancer xenograft. PC-346C has a nonsense mutation on the MMAC/ PTEN whereas it is wild type for p53.
Three adenoviral vectors were constructed (Canji Inc., San Diego, USA): Ad5-CMV-MMAC/PTEN (wild type MMAC/PTEN gene), Ad-5-CMV-p53 (wild type p53) and Ad5-CMV-EGFP (enhanced GFP).
At an MOI of 10, 50% growth suppression was observed in PC-346C for Ad5-CMV-MMAC/PTEN as compared to the p53 and EGFP controls.
Conclusion
The transduction ef®cacy of retargeted adenoviral vectors is increased especially in poorly differentiated prostate cancer cell lines. Retargeting may increase speci®city of gene therapeutic vectors, and reduce the hepatotoxicity after systemic application in vivo. Next to cytotoxic or immunomodulatory payloads, PTEN is a potential therapeutic gene.
